5.Conclusion
The Fingolimod plus standard treatment group resulted in more ischemic penumbra rescue and improved clinical function than the standard treatment. A higher proportion of patients with MRS 0–1 at 90 days in the fingolimod plus standard group than the standard treatment group. Fingolimod plus standard treatment showed a decrease in NIHSS score at 24 hours compared with standard treatment. However, the trend did not persist through 7 days, and there was no statistically significant decrease in NIHSS scores at 7 days compared to the standard treatment group. Still, there was a statistically significant decrease at 90 days. The fingolimod plus standard treatment group showed less lesion enlargement at 24 hours than the standard treatment group. The trend continued for 7 days. There was no significant difference in the incidence of complications and adverse events between the standard treatment group and fingolimod plus standard treatment group. Our study shows that it is feasible to use fingolimod to treat AIS.
Abbreviations: AIS: Acute ischemic stroke, PRISMA: Preferred Reporting Items for Systemic Reviews and Meta-Analysis, MRS: Modified Rankin Scale, MD: mean difference, RCTs: Randomized controlled trials,tPA: tissue plasminogen activator, BBB: blood-brain barrier, MeSH: Medical Subject Heading, NIHSS: National Institutes of Health Stroke Scale, CI: confidence interval, RR: risk ratio, SAEs: serious adverse events, AEs: adverse events, S1PR: sphingosine-1-phosphate receptors, MS: multiple sclerosis.CNS: Central nervous system, PB: Peng Bai, NL: Na Li, JY: Jun Yuan, RZ: Runxiu Zhu, PW: Ping Wang, FJ: Feng Jiang, JZ: Jin Zhen, YY: Yuan Yao, CZ: Chenhui Zhao, ZL: Zihong Liang, MW: Meiling Wang, BL: Bin Liu, ML: Min Li.